Patents by Inventor Seth Cabot Hopkins
Seth Cabot Hopkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404924Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: March 7, 2023Publication date: December 21, 2023Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
-
Publication number: 20230285356Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: October 31, 2022Publication date: September 14, 2023Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Patent number: 11738002Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 13, 2021Date of Patent: August 29, 2023Assignee: Sunovion Pharmaceuticals Inc.Inventors: Carrie A. Bowen, Seth Cabot Hopkins, Colleen M. Synan
-
Publication number: 20230241024Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided herein is Compound 1: or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders associated with metabolic disorders.Type: ApplicationFiled: September 21, 2022Publication date: August 3, 2023Applicant: Sunovion Pharmaceuticals Inc.Inventors: Linda Jane BRISTOW, Nina DEDIC, Eva HAJOS-KORCSOK, Seth Cabot HOPKINS, Philip Glyn JONES, Kenneth S. KOBLAN, Snezana MILANOVIC, Colleen Marie SYNAN, Kuangnan XIONG
-
Patent number: 11654113Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: September 30, 2021Date of Patent: May 23, 2023Assignee: Sunovion Pharmaceuticals Inc.Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
-
Patent number: 11517558Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: November 13, 2020Date of Patent: December 6, 2022Assignee: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Publication number: 20220323409Abstract: Provided are modified release compositions in a solid oral dosage form comprising racemic amisulpride, or pharmaceutically acceptable salts thereof, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.Type: ApplicationFiled: June 4, 2020Publication date: October 13, 2022Inventors: Takumi ASADA, Gerald R. GALLUPPI, Seth Cabot HOPKINS, Megumi MARUYAMA, Siriporn TOONGSUWAN, Yuki TSUSHIMA
-
Publication number: 20220117899Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: September 30, 2021Publication date: April 21, 2022Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
-
Patent number: 11160758Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: June 4, 2020Date of Patent: November 2, 2021Assignee: Sunovion Pharmaceuticals Inc.Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
-
Publication number: 20210315859Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 13, 2021Publication date: October 14, 2021Inventors: Carrie A. BOWEN, Seth Cabot HOPKINS, Colleen M. SYNAN
-
Publication number: 20210315860Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: November 13, 2020Publication date: October 14, 2021Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Patent number: 10874639Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: April 13, 2020Date of Patent: December 29, 2020Assignee: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Publication number: 20200383924Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: June 4, 2020Publication date: December 10, 2020Inventors: Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
-
Publication number: 20200237719Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: April 13, 2020Publication date: July 30, 2020Applicant: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Publication number: 20200179336Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 5, 2019Publication date: June 11, 2020Applicant: Sunovion Pharmaceuticals Inc.Inventor: Seth Cabot HOPKINS
-
Patent number: 10660875Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: January 9, 2020Date of Patent: May 26, 2020Assignee: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Publication number: 20200147040Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: January 9, 2020Publication date: May 14, 2020Applicant: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Patent number: 10576058Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: June 26, 2019Date of Patent: March 3, 2020Assignee: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Publication number: 20190314331Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: ApplicationFiled: June 26, 2019Publication date: October 17, 2019Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
-
Patent number: 10369134Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.Type: GrantFiled: December 4, 2018Date of Patent: August 6, 2019Assignee: Sunovion Pharmaceuticals Inc.Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson